STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #86 by analyst upside · 2026-06-27
RANI
Rani Therapeutics Holdings, Inc.
Healthcare · Market Cap $101M · P/E 0x
ANALYST PRICE TARGET
+919.2%
implied upside to consensus target
Current Price $0.74
Consensus Target $7.5
Bull Target $11.0
Bear Target $5.0
Analysts Covering 4
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
3
Hold
0
Sell
0
52-Week Low $0.39
52-Week High $3.87
YTD Return -45.9%
FUNDAMENTALS
Market Cap $101M
P/E Ratio (TTM) N/A
Forward P/E -3.3x
EPS (TTM) $-0.27
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $3M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.39
52-Week High $3.87
Current Price $0.74
Bear Target $5.0
Bull Target $11.0
● Now $0.74 ● Target $7.5
TRADING DATA
Avg Volume 1.0M
YTD Return -45.9%
Analyst Count 4
Consensus Buy
Upside to Target +919.2%
Last Updated 2026-06-27

ANALYST SUMMARY

Rani Therapeutics Holdings, Inc. (RANI) is currently trading at $0.74 with a Wall Street consensus price target of $7.5, implying potential upside of 919.2% over the next 12 months. 4 analysts currently cover RANI, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $11.0, while the most cautious has a target of $5.0.

RANI operates in the Healthcare sector with a market capitalisation of $101M. The stock is down 45.9% year-to-date and is currently trading near the lower end of its 52-week range of $0.39 – $3.87.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RANI, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity — Reiterated
Buy → Buy 2026-05-20 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2026-04-01 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-03-27 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-01-09 31% win rate (48 calls)
Maxim Group — Reiterated
Buy → Buy 2025-10-20 28% win rate (40 calls)
Oppenheimer — Reiterated
Outperform → Outperform 2025-05-16 14% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-04-03 31% win rate (48 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2025-02-26 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
39
out of 100
Coverage depth
12/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →